Robert A. Figlin
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Renal cell carcinoma treatment
- Cancer Research top 0.05%
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Renal cell carcinoma treatment 204
-
- Cancer Genomics and Diagnostics 65
- Co-authors
- Arie S. Belldegrun (135 shared papers)Robert John Motzer (36 shared papers)Thomas E. Hutson (36 shared papers)Allan J. Pantuck (61 shared papers)Stéphane Marie. Oudard (7 shared papers)Ronald M. Bukowski (22 shared papers)Piotr Tomczak (4 shared papers)Marc Dror Michaelson (16 shared papers)
- Journals
- The Journal of Urology (54 papers)Cancer (29 papers)Journal of Clinical Oncology (27 papers)Clinical Cancer Research (16 papers)Journal of Immunotherapy (13 papers)
- Partner nations
- United StatesFranceItaly
In The Last Decade
Robert A. Figlin
384 papers receiving 40.0k citations
Robert A. Figlin's Hit Papers
Peers
Comparison fields: 5 of 163
- Pulmonary and Respiratory Medicine 23.9k
- Cancer Research 9.3k
- Oncology 9.6k
- Molecular Biology 16.7k
- Immunology 3.1k
Countries citing papers authored by Robert A. Figlin
This map shows the geographic impact of Robert A. Figlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Figlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Figlin more than expected).
Fields of papers citing papers by Robert A. Figlin
This network shows the impact of papers produced by Robert A. Figlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Figlin. The network helps show where Robert A. Figlin may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert A. Figlin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 391 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4810 |
| 2 | Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 3042 |
| 3 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Hit paper breakdown → | 2008 | 2538 |
| 4 | Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2009 | 1843 |
| 5 | Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2005 | 1379 |
| 6 | Phase 3 trial of everolimus for metastatic renal cell carcinoma Hit paper breakdown → | 2010 | 983 |
| 7 | Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Hit paper breakdown → | 2003 | 644 |
| 8 | Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience Hit paper breakdown → | 2005 | 595 |
| 9 | Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System Hit paper breakdown → | 2001 | 593 |
| 10 | Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. | 2003 | 562 |
| 11 | Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma Hit paper breakdown → | 2002 | 538 |
| 12 | Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Hit paper breakdown → | 2011 | 490 |
| 13 | 2009 | 430 | |
| 14 | 2004 | 421 | |
| 15 | 2017 | 414 | |
| 16 | Kidney Cancer Hit paper breakdown → | 2009 | 403 |
| 17 | 2000 | 362 | |
| 18 | A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma Hit paper breakdown → | 2013 | 356 |
| 19 | 2017 | 337 | |
| 20 | 2004 | 324 |
About Robert A. Figlin
Robert A. Figlin is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Immunology and Molecular Biology, having authored 391 papers that have together received 41.4k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (204 papers), Renal and related cancers (65 papers), Cancer Genomics and Diagnostics (65 papers), Cancer Immunotherapy and Biomarkers (41 papers), Immunotherapy and Immune Responses (27 papers), Bladder and Urothelial Cancer Treatments (25 papers), CAR-T cell therapy research (19 papers) and Immune Cell Function and Interaction (17 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (23.9k citations), Cancer Research (9.3k citations), Oncology (9.6k citations), Molecular Biology (16.7k citations) and Immunology (3.1k citations). Robert A. Figlin has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Arie S. Belldegrun, Robert John Motzer, Thomas E. Hutson, Allan J. Pantuck, Stéphane Marie. Oudard, Ronald M. Bukowski, Piotr Tomczak, Marc Dror Michaelson, Sindy T. Kim and Sylvie Négrier. Their work appears in journals such as The Journal of Urology, Cancer, Journal of Clinical Oncology, Clinical Cancer Research and Journal of Immunotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.